Original Research

Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

Weiss L, Gary D, Swern AS, Freeman J, Sugrue MM

Therapeutics and Clinical Risk Management 2015, 11:1355-1360

Published Date: 4 September 2015